Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer

Urology

Volumn 77, Issue 3, 2011, Pages 682-687

  Mountzios, Ioannis ^a   Bournakis, Evangelos ^a   Efstathiou, Eleni ^a,b   Varkaris, Andreas ^a   Wen, Sijin ^b   Chrisofos, Michael ^a   Deliveliotis, Charalambos ^a   Alamanis, Christos ^a   Anastasiou, Ioannis ^a   Constantinides, Constantine ^a   Karadimou, Alexandra ^a   Tsiatas, Marinos ^a   Papadimitriou, Christos ^a   Bamias, Aristotelis ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CASTRATE RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LACRIMATION; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAIL DYSTROPHY; NAUSEA AND VOMITING; NEUROMUSCULAR DISEASE; NEUTROPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RETREATMENT; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORCHIECTOMY; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS;

EID: 79952360061     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.08.044     Document Type: Article

References (17)

1. A.M. Lin, C.J. Ryan, and E.J. Small Intermittent chemotherapy for metastatic hormone refractory prostate cancer Crit Rev Oncol Hematol 61 2007 243 254 (Pubitemid 46329430)
2. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
3. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
4. S.L. Goldenberg, N. Bruchovsky, and M.E. Gleave Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Urology 45 1995 839 844
5. C.S. Higano, W. Ellis, and K. Russell Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study Urology 48 1996 800 804 (Pubitemid 26409365)
6. T.M. Beer, M. Garzotto, and W.D. Henner Intermittent chemotherapy in metastatic androgen-independent prostate cancer Br J Cancer 89 2003 968 970 (Pubitemid 37239196)
7. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in metastatic, androgen-independent prostate cancer: initial results from ASCENT. Presented at the American Society of Clinical Oncology, 2006.
8. Miller K, Wulfing C, Lehmann J, et al. Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition: preliminary results of a multicenter phase II study (AUOAP33/02). Presented at the American Society of Clinical Oncology, 2005.
9. E. Efstathiou, G. Bozas, and A. Kostakopoulos Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment Urology 65 2005 126 130 (Pubitemid 40169618)
10. C.M. Gundy, and N.K. Aaronson Effects of mode of administration (MOA) on the measurement properties of the EORTC QLQ-C30: a randomized study Health Qual Life Outcomes 8 2010 35 38
11. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. T.M. Beer, M. Garzotto, and W.D. Henner Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer Br J Cancer 91 2004 1425 1427 (Pubitemid 39486342)
13. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in metastatic, androgen-independent prostate cancer: initial results from ASCENT. Presented at the American Society of Clinical Oncology Multi-disciplinary Prostate Cancer Symposium 2006.
14. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467 (Pubitemid 29517916)
15. S. Halabi, N.J. Vogelzang, and S.S. Ou Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer J Clin Oncol 27 2009 2766 2771
16. D.P. Petrylak, D.P. Ankerst, and C.S. Jiang Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 J Natl Cancer Inst 98 2006 516 521 (Pubitemid 43898814)
17. H.B. Muss, L.D. Case, F. Richards II Piedmont Oncology Association Interrupted versus continuous chemotherapy in patients with metastatic breast cancer N Engl J Med 325 1991 1342 1348